Cidara Theraptcs Stock Price, News & Analysis

Cidara Therapeutics (Nasdaq: CDTX), a biotechnology company specializing in drug-Fc conjugate therapeutics through its Cloudbreak® platform, has announced plans for a $250.0 million underwritten public offering of common stock. The company intends to grant underwriters a 30-day option to purchase up to an additional 15% of shares.

The offering will be managed by joint book-runners J.P. Morgan, Morgan Stanley, Guggenheim Securities, and Cantor. The offering is being made through a shelf registration statement on Form S-3 that was declared effective by the SEC on May 15, 2025.

Cidara Therapeutics (NASDAQ: CDTX) announced positive topline results from its Phase 2b NAVIGATE trial evaluating CD388, a novel drug-Fc conjugate for preventing seasonal influenza. The trial demonstrated significant protection efficacy across all dose groups, with a single dose providing up to 76% protection over 24 weeks compared to placebo. The 450mg dose showed the highest efficacy (76.1%), followed by 300mg (61.3%) and 150mg (57.7%). The study met its primary endpoint and all secondary endpoints, including efficacy at different temperature thresholds and protection lasting up to 28 weeks. CD388 was well-tolerated across all doses with no safety concerns or drug-related serious adverse events. The company has submitted an end of Phase 2 meeting request to the FDA to discuss Phase 3 trial design.

Cidara Therapeutics (NASDAQ: CDTX) announced it will host a virtual R&D day on May 22, 2025, from 10:00 to 11:30 AM ET to discuss CD388, their innovative long-acting antiviral drug designed for universal, once-per-flu season prevention of seasonal and pandemic influenza.

The event will feature key opinion leaders Dr. Fred Hayden from the University of Virginia School of Medicine and Dr. Rick Bright from the Pandemic Prevention Institute. Topics will include the 2024-2025 flu season review, updates on the ongoing Phase 2b NAVIGATE trial's statistical analysis plan, planned Phase 3 study design, commercial opportunities, and competitive landscape for CD388.

Cidara Therapeutics (NASDAQ: CDTX), a biotechnology company specializing in drug-Fc conjugate therapeutics through its Cloudbreak® platform, has announced its participation in two upcoming investor conferences. The company will present at the RBC Global Healthcare Conference on May 21, 2025, at 10:00 AM ET, and the Jefferies Global Healthcare Conference on June 4, 2025, at 11:40 AM ET.

Both presentations will be available via live webcast through Cidara's investor relations website, with replays accessible for at least 30 days. The company will also engage in one-on-one meetings with investors during these events.

Cidara Therapeutics (CDTX) provided its Q1 2025 financial results and corporate updates. The company reached a key milestone with the data cutoff for its Phase 2b NAVIGATE trial on April 30, 2025, involving 5,041 subjects testing CD388 for influenza prevention. Top-line results are expected in late June 2025.

Key financial highlights include: cash position of $174.5M as of March 31, 2025, down from $196.2M in December 2024. Q1 2025 saw increased R&D expenses of $24.6M (vs $5.9M in Q1 2024) and a net loss of $23.5M (vs $10.3M in Q1 2024).

The company published preclinical data in Nature Microbiology highlighting CD388's potential as a universal antiviral for influenza prevention. Additionally, Cidara promoted Nicole Davarpanah to Chief Medical Officer and Corrina Pavetto to Senior Vice President of Clinical Development.

Cidara Therapeutics (NASDAQ: CDTX) has announced key leadership promotions effective May 1, 2025. Dr. Nicole Davarpanah has been elevated to Chief Medical Officer (CMO), while Corrina Pavetto has been promoted to Senior Vice President of Clinical Development. These appointments come as Cidara advances its influenza antiviral candidate CD388 through Phase 2b NAVIGATE trial and prepares for Phase 3. Dr. Davarpanah brings over a decade of clinical development experience, including 6 years at Genentech/Roche, and holds both M.D. and J.D. degrees. Pavetto contributes 25+ years of clinical research experience, particularly in infectious disease, with previous experience at BARDA overseeing influenza antiviral and vaccine development programs.

Cidara Therapeutics (Nasdaq: CDTX), a biotech company specializing in drug-Fc conjugate therapeutics through their proprietary Cloudbreak® platform, has announced their upcoming participation in The Citizens Life Sciences Conference.

The event details include:

• Conference: The Citizens Life Sciences Conference
• Date: Wednesday, May 7, 2025
• Time: 11:00 AM ET
• Format: Presentation

The presentation will be accessible via webcast, and a replay will be available in the Investors section of Cidara's website for at least 30 days. The company will also engage in one-on-one investor meetings during the event.

Cidara Therapeutics (CDTX), a biotechnology company specializing in drug-Fc conjugate immunotherapies through its proprietary Cloudbreak® platform, has scheduled its first quarter 2025 financial results announcement for May 8, 2025. The results will be released after U.S. market close, followed by a conference call and webcast at 5:00 PM Eastern Time to discuss financial performance and provide operational updates.

Cidara Therapeutics (CDTX) has granted equity awards to new employee Timothy Alefantis under its 2020 Inducement Incentive Plan. The compensation package includes:

• Non-qualified stock options and RSUs totaling 27,000 shares
• Stock option exercise price set at $21.54 per share (closing price on March 31, 2025)
• Options vest over 4 years: 25% after first year, remaining in 36 monthly installments
• RSUs vest in 4 equal annual installments on quarterly vesting dates (March 10, June 10, September 10, or December 10)

These awards were granted as employment inducements in accordance with Nasdaq Listing Rule 5635(c)(4), specifically designed for new employees who were not previously with Cidara.